Select Page

2017 Corporate Citizenship Report:

Our Purpose Our Impact

2017 Corporate Citizenship Report

At Biogen, our mission is clear: we are pioneers in neuroscience. Our commitment to transforming the lives of patients and leading in the field of neuroscience is unwavering. Using our understanding and expertise, we have pioneered drug discovery and have improved the understanding surrounding some of the most complex neurological conditions that patients and healthcare providers face each and every day, such as multiple sclerosis (MS) and spinal muscular atrophy (SMA).

Our philosophy is Caring Deeply. Working Fearlessly. Changing Lives.™ Beyond our leadership in the development of new and ground-breaking therapies, we strive to improve overall patient health outcomes, positively impact social and environmental challenges, cultivate a workplace that enables our employees to thrive, support local communities and inspire future generations of scientists. We believe this philosophy is central to our mission as we build on our legacy of science and discovery to pursue increasingly complex challenges in neuroscience.

  2017 Corporate Citizenship Report:

  Our Purpose, Our Impact

At Biogen, our mission is clear: we are pioneers in neuroscience. Our commitment to transforming the lives of patients and leading in the field of neuroscience is unwavering. Using our understanding and expertise, we have pioneered drug discovery and have improved the understanding surrounding some of the most complex neurological conditions that patients and healthcare providers face each and every day, such as multiple sclerosis (MS) and spinal muscular atrophy (SMA).

Our philosophy is Caring Deeply. Working Fearlessly. Changing Lives.™ Beyond our leadership in the development of new and ground-breaking therapies, we strive to improve overall patient health outcomes, positively impact social and environmental challenges, cultivate a workplace that enables our employees to thrive, support local communities and inspire future generations of scientists. We believe this philosophy is central to our mission as we build on our legacy of science and discovery to pursue increasingly complex challenges in neuroscience.

2017 Highlights

$12.3B

(US Dollars) in revenue in 2017

employees worldwide

1st

and only approved treatment for spinal muscular atrophy (SMA)

%

of MS patients worldwide treated with Biogen products as of March 31, 2018¹

%

reduction in operational carbon intensity since 2006

Carbon Neutral

company since 2014

%

of positions at the director level and above are held by women

consecutive years ‘Best Place to Work’ for LGBT equality in the U.S.

employees in 26 countries supported over 60 projects as part of Care Deeply Day in 2017

$6.2M

in community grants including Biogen Foundation employee matching gift donations ($1.7 million) in 2017

students along with 524 employee volunteers participated in our Community Lab programs to learn more about science and technology

%

engaged with ten suppliers representing 36% of our supply chain total GHG emissions

$12.3B
(US Dollars) in revenue in 2017
7,000+
employees worldwide
36%

of MS patients treated with our medicines globally as of March 31st, 2018¹

1st
and only approved treatment for spinal muscular atrophy (SMA)
75%
reduction in operational carbon intensity since 2006
Carbon Neutral
company since 2014
43%
of positions at the director level and above are held by women
4

consecutive years ‘Best Place to Work’ for LGBT equality in the U.S.

2,600
employees in 26 countries supported over 60 projects as part of Care Deeply Day in 2017
$6.2M

in community grants including Biogen Foundation employee matching gift donations ($1.7 million) in 2017

5,133
students along with 524 employee volunteers participated in our Community Lab programs to learn more about science and technology
36%
engaged with ten suppliers representing 36% of our supply chain total GHG emissions

Footnotes:

  1. Biogen data on file.

External Awards & Recognition

  • Dow Jones Sustainable World Index in 2017 – #2 Biotech company
  • Four Consecutive Years ‘Best Place to Work’ for LGBT Equality in the U.S. by the Human Rights Campaign
  • 100 Best Corporate Citizens for 2017 by CR Magazine
  • #1 on IDEA Pharma’s 2017 Pharmaceutical Innovation Index
  • Top Biotech Company – Calvert Diversity Report (score of 95 out of 100, one of ten companies and only biotech company to achieve this recognition)
  • 2017 Prix Galien USA Award for Best Biotechnology Product along with Ionis Pharmaceuticals for SPINRAZA®
  • Ranked one of the “Just 100” – America’s Most Just companies list by Forbes and Just Capital
  • Human Rights Campaign Corporate Equality
 Index – Received a perfect score of 100 for 2017
  • One of 136 leading businesses committed to 100% renewable power via RE100
  • 90% score on the Disability Equality Index (DEI)
  • The Sustainability Yearbook – RobescoSAM Bronze Class (2017)
  • 2017 Beacon Award for Diversity & Inclusion by the Boston Bar Association
  • 2017 Commitment to Diversity Xconomy Award for work with Women In Bio and Raising the Bar
  • Biogen Foundation awarded the US 2020 STEM Mentoring Award for work with WakeEd Partnership
  • #15 in the U.S. on Newsweek’s 2017 Green Rankings
  • #18 on Forbes’ America’s Best Midsize Employers
  • Environmental Protection Agency’s Green Power Top 100 list – 100% Green Power User
  • Named one of top charitable contributors in Massachusetts by Boston Business Journal

Report Archive

Forward-Looking Statement

This report contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Biogen’s business activities; Biogen’s strategy and plans; potential of Biogen’s commercial business and pipeline programs; capital allocation and investment strategy; clinical trials and data readouts and presentations; regulatory filings and the timing thereof; and anticipated benefits and potential of investments, collaborations and business development activities. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including risks relating to difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for Biogen’s products; the occurrence of adverse safety events, restrictions on use with Biogen’s products or product liability claims; uncertainty of success in developing, licensing or acquiring other product candidates or additional indications for existing products; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including Biogen’s ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies or may fail to approve or may delay approval of our drug candidates;; problems with Biogen’s manufacturing processes; Biogen’s dependence on collaborators and other third parties for the development, regulatory approval and commercialization of products and other aspects of Biogen’s business, which are outside of Biogen’s control; failure to successfully execute on Biogen’s growth initiatives; risks relating to investment in and expansion of manufacturing capacity for future clinical and commercial requirements; failure to comply with legal and regulatory requirements; environmental risks; risks relating to the sale and distribution by third parties of counterfeit versions of Biogen’s products; and the other risks identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission.

These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this report. Biogen does not undertake any obligation to publicly update any forward-looking statements.